Resumen
Purpose: Guidelines for the use of goal attainment scaling (GAS) recommend that the patient specify at least three goals. Even so, this may not always be feasible or align with patient preferences. Investigations into the psychometric properties of GAS using three or more goals largely support its reliability, validity, and responsiveness compared with standard measures. As evaluations of responsiveness rely on variability estimates, this metric may be impacted when GAS is based on fewer than three goals. For this reason, we investigated the responsiveness of one- and two-goal GAS. Methods: Secondary analyses were conducted on data from a mixed sample of pediatric, adolescent and adult subjects with hemophilia A. The standardized response mean (SRM) and its 95% confidence intervals (CI) were used to assess responsiveness of one- and two-goal GAS at six and twelve weeks. Results: Both one-goal and two-goal GAS demonstrated similar responsiveness to change at 6-week (Patient-Rated GAS: one-goal SRM [95% CI] = 0.70 [0.45–1.08], two-goal = 0.96 [0.68–1.30]; Clinician-Rated GAS: one-goal = 1.26 [0.81–1.77], two-goal = 1.01 [0.73–1.32]) and 12-week follow-up (Patient-Rated GAS: one-goal SRM [95% CI] = 1.14 [0.53–1.71], two-goal = 1.35 [0.92–1.82]; Clinician-Rated GAS: one-goal = 1.71 [1.12–2.30], two-goal = 1.48 [1.02–2.02]). Larger SRMs were observed for clinician-rated GAS, but all were within the rubric of a large effect size. Conclusions: One-goal GAS is responsive to change in a clinical population. Further research is recommended in a larger sample where responsiveness of one- and multiple-goal GAS can be compared
| Idioma original | English |
|---|---|
| Número de artículo | 20 |
| Publicación | Journal of Patient-Reported Outcomes |
| Volumen | 3 |
| N.º | 1 |
| DOI | |
| Estado | Published - dic. 1 2019 |
Nota bibliográfica
Funding Information:KR receives career support from the Dalhousie Medical Research Foundation as the Kathryn Allen Weldon Professor of Alzheimer Research at Dalhousie University Halifax, Nova Scotia, Canada, and receives research support from the Canadian Institutes of Health Research (grant no. PJT-156114). LM received a postdoctoral fellowship from the Mitacs Elevate program (Ref: IT09427). The data related to one-goal GAS is sourced from a study funded by Shire.
Funding Information:
KR is the founder, President, Chief Science Officer and majority shareholder of DGI Clinical Inc., a company that had a contractual agreement with Baxalta US Inc., now part of Shire, to study individualized outcome measures in haemophilia. LM is a Mitacs postdoctoral fellow whose industrial co-sponsor is DGI Clinical, Halifax, Nova Scotia, Canada. JCR has received investigator-initiated research grant support, has served as a consultant, received travel support, and served on a speaker’s bureau for Baxalta US Inc. and Shire. MD is an employee and shareholder of Shire.
Funding Information:
Not applicable. KR receives career support from the Dalhousie Medical Research Foundation as the Kathryn Allen Weldon Professor of Alzheimer Research at Dalhousie University Halifax, Nova Scotia, Canada, and receives research support from the Canadian Institutes of Health Research (grant no. PJT-156114). LM received a postdoctoral fellowship from the Mitacs Elevate program (Ref: IT09427). The data related to one-goal GAS is sourced from a study funded by Shire. The data that support the findings of this study are available from Shire but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Shire.
Publisher Copyright:
© 2019, The Author(s).
ASJC Scopus Subject Areas
- Health Informatics
- Health Information Management
PubMed: MeSH publication types
- Journal Article